Clinical Trial Detail

NCT ID NCT03195491
Title A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.